Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse
Chinmayee Sethy, Kunal Goutam, Deepika Nayak, et al.
Journal of Cancer Research and Clinical Oncology (2019) Vol. 146, Iss. 1, pp. 245-259
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition
Chinmayee Sethy, Chanakya Nath Kundu
Biomedicine & Pharmacotherapy (2021) Vol. 137, pp. 111285-111285
Open Access | Times Cited: 391
Nano formulated Resveratrol inhibits metastasis and angiogenesis by reducing inflammatory cytokines in oral cancer cells by targeting tumor associated macrophages
Rajalaxmi Pradhan, Subhajit Chatterjee, Krushna Chandra Hembram, et al.
The Journal of Nutritional Biochemistry (2021) Vol. 92, pp. 108624-108624
Closed Access | Times Cited: 70
Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy
Subhajit Chatterjee, Saptarshi Sinha, Chanakya Nath Kundu
European Journal of Pharmacology (2021) Vol. 911, pp. 174516-174516
Closed Access | Times Cited: 60
The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review
Wafa Bouleftour, Aline Guillot, Nicolas Magné
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 4, pp. 493-501
Open Access | Times Cited: 43
Therapeutic prospects of nectin-4 in cancer: applications and value
Kaiyue Li, Yujing Zhou, Maolin Zang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 13
Emerging Targets in Non-Small Cell Lung Cancer
Louisa Liu, Joshua Soler, Karen L. Reckamp, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10046-10046
Open Access | Times Cited: 7
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment
S. Acharya, Chanakya Nath Kundu
Cancer Treatment Reviews (2024) Vol. 127, pp. 102749-102749
Closed Access | Times Cited: 6
PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO)
Subhajit Chatterjee, Saptarshi Sinha, Sefinew Molla, et al.
Cellular Signalling (2020) Vol. 80, pp. 109902-109902
Closed Access | Times Cited: 42
The mechanisms of renin–angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures
Haifeng Zhang, Xiang Gao, Xuan Wang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111868-111868
Open Access | Times Cited: 36
Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis
Chinmayee Sethy, Kunal Goutam, Biswajit Das, et al.
Vascular Pharmacology (2021) Vol. 140, pp. 106865-106865
Closed Access | Times Cited: 33
Quinacrine inhibits HIF-1α/VEGF-A mediated angiogenesis by disrupting the interaction between cMET and ABCG2 in patient-derived breast cancer stem cells
Biswajit Das, Somya Ranjan Dash, Harun Patel, et al.
Phytomedicine (2023) Vol. 117, pp. 154914-154914
Closed Access | Times Cited: 16
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Wei Zhou, Peng Fang, Dongan Yu, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 8, pp. 913-925
Open Access | Times Cited: 13
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma
Jeffrey L. Wong, Jonathan E. Rosenberg
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 7, pp. 863-873
Open Access | Times Cited: 31
Nectin-4: a Novel Therapeutic Target for Skin Cancers
Hiroki Hashimoto, Yuka Tanaka, Maho Murata, et al.
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 4, pp. 578-593
Closed Access | Times Cited: 19
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development
Roberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
British Journal of Cancer (2023)
Open Access | Times Cited: 12
Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy
N. C. Ganguli, Puja Kumari, Sagarika Dash, et al.
Biochemical and Biophysical Research Communications (2023) Vol. 677, pp. 31-37
Closed Access | Times Cited: 11
Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation
Saptarshi Sinha, Subarno Paul, S. Acharya, et al.
Medical Oncology (2024) Vol. 41, Iss. 2
Closed Access | Times Cited: 4
Emerging roles of the nectin family of cell adhesion molecules in tumour-associated pathways
Kheerthana Duraivelan, Dibyendu Samanta
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188589-188589
Closed Access | Times Cited: 24
Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway
Saptarshi Sinha, Subhajit Chatterjee, Subarno Paul, et al.
Experimental Cell Research (2022) Vol. 420, Iss. 1, pp. 113338-113338
Closed Access | Times Cited: 18
Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma
Yuka Tanaka, Maho Murata, Keiko Tanegashima, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells
Subarno Paul, Subhajit Chatterjee, Saptarshi Sinha, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 10, pp. 999-1015
Closed Access | Times Cited: 9
Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300
Chinmay Das, Somya Ranjan Dash, Saptarshi Sinha, et al.
Medical Oncology (2023) Vol. 40, Iss. 12
Open Access | Times Cited: 8
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
Catherine C. Fahey, Caroline A. Nebhan, Sally J. York, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16109-16109
Open Access | Times Cited: 8
Differences of Angiogenesis Factors in Tumor and Diabetes Mellitus
Shidong Tan, Guangyao Zang, Ying Wang, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 3375-3388
Open Access | Times Cited: 19
Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response
Jun Nagayama, Satoshi Inoue, Hiroki Sai, et al.
International Journal of Clinical Oncology (2024) Vol. 30, Iss. 2, pp. 267-276
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top